Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 14, 2014; 20(38): 13648-13657
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13648
Figure 3
Figure 3 Positron emission tomography with the glucose analog fluorine-18 fluorodeoxyglucose studies in patients with clinically responding and nonresponding tumors[75]. A: In the responding tumor, fluorodeoxyglucose (FDG) uptake decreases to background level 14 d after initiation of chemotherapy; B: In contrast, FDG uptake is almost unchanged for the nonresponding tumor. Copyright © 2003 American Society of Clinical Oncology.